CD274 and neoplasm: Anti-VEGF therapies can reduce VEGF-mediated immunosuppression within the tumor and its microenvironment and may enhance anti-PD-1/PD-L1 efficacy by reversing VEGF-mediated immunosuppression and promoting tumor T-cell infiltration (Hegde et al., 2018).